Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.0K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.0K
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

255
Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
255
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

497
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
497
Regulation of Sodium and Potassium01:26

Regulation of Sodium and Potassium

1.7K
The regulation of sodium and potassium ion concentrations in the human body is a complex process governed primarily by hormones such as aldosterone, antidiuretic hormone (ADH), and atrial natriuretic peptide (ANP).
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
1.7K
Roles of Electrolytes: Sodium and Potassium01:24

Roles of Electrolytes: Sodium and Potassium

1.7K
Sodium plays a crucial role in maintaining fluid and electrolyte balance and overall bodily homeostasis. Sodium balance is primarily regulated by kidney function, which adjusts sodium elimination to match dietary intake and maintain proper electrolyte levels. Sodium is the most abundant cation in the extracellular fluid (ECF) and is found in salts such as sodium chloride (NaCl) and sodium bicarbonate (NaHCO3). Although cellular plasma membranes are relatively impermeable to sodium, its role in...
1.7K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.7K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Finerenone and Blood Pressure in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Randomized Clinical Trial.

JAMA cardiology·2026
Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Global heart·2026
Same author

Health Status in Heart Failure With Preserved Ejection Fraction in Asia: Insights From Global Trials.

JACC. Asia·2026
Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

European heart journal·2026
Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Circulation·2026
Same author

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Journal of the American College of Cardiology·2026

Related Experiment Video

Updated: Dec 11, 2025

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

3.3K

Serum potassium in the PARADIGM-HF trial.

João Pedro Ferreira1,2, Ulrik M Mogensen3, Pardeep S Jhund2

  • 1National Institute of Health and Medical Research, Centre for Clinical Multidisciplinary Research, INSERM U1116, University of Lorraine, Regional University Hospital of Nancy, French Clinical Research Infrastructure Network Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists, Nancy, France.

European Journal of Heart Failure
|August 19, 2020
PubMed
Summary

Both high and low potassium levels increase cardiovascular death risk in heart failure patients. Sacubitril-valsartan showed consistent benefits across all potassium levels, with no overall effect on potassium. Potassium levels appear to be risk markers, not mediators.

Keywords:
HyperkalaemiaHypokalaemiaMineralocorticoid receptor antagonistsOutcomesPotassiumSacubitril-valsartan

More Related Videos

Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain
11:20

Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain

Published on: May 7, 2018

12.5K
A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels
05:31

A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels

Published on: April 24, 2012

14.8K

Related Experiment Videos

Last Updated: Dec 11, 2025

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique
08:11

Voltage-Dependent Potassium Current Recording on H9c2 Cardiomyocytes via the Whole-Cell Patch-Clamp Technique

Published on: November 11, 2022

3.3K
Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain
11:20

Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain

Published on: May 7, 2018

12.5K
A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels
05:31

A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels

Published on: April 24, 2012

14.8K

Area of Science:

  • Cardiology
  • Clinical Pharmacology

Background:

  • Potassium levels are crucial in cardiovascular health.
  • Abnormal potassium (hyperkalemia and hypokalemia) is common in heart failure.
  • The impact of potassium on heart failure outcomes and treatment response needs clarification.

Purpose of the Study:

  • To investigate the association between potassium levels and outcomes in heart failure with reduced ejection fraction (HFrEF).
  • To determine the effect of sacubitril-valsartan on potassium levels.
  • To assess if potassium levels modify the efficacy of sacubitril-valsartan compared to enalapril in HFrEF patients.

Main Methods:

  • Analysis of data from the PARADIGM-HF trial involving 8399 patients with HFrEF.
  • Potassium levels were analyzed as continuous and categorical variables (hypokalemia ≤3.5 mmol/L, hyperkalemia ≥5.5 mmol/L).
  • Outcomes included cardiovascular death, sudden death, pump failure death, non-cardiovascular death, and heart failure hospitalization.

Main Results:

  • Both hypokalemia and hyperkalemia were associated with increased risk of cardiovascular death compared to normal potassium levels (4.1-4.9 mmol/L).
  • Potassium abnormalities showed similar associations with other adverse outcomes like sudden death, pump failure death, and hospitalizations.
  • Sacubitril-valsartan demonstrated consistent benefits across the spectrum of baseline potassium levels and did not significantly alter potassium levels overall.

Conclusions:

  • Abnormal potassium levels (both high and low) are independent predictors of cardiovascular death in HFrEF patients.
  • Potassium abnormalities may serve as indicators of risk rather than direct causes of mortality.
  • The therapeutic advantages of sacubitril-valsartan in HFrEF are not influenced by baseline potassium status.